OPTImization of the Dose of tacroliMUS by Bayesian Prediction
Status:
Completed
Trial end date:
2020-09-21
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of tacrolimus (TAC) are characterized by high inter- and
intra-individual variability with narrow therapeutic range. Currently, the limiting point of
Tac drug monitoring is the inability to individualize doses during the first few days after
transplantation. Our group developed a population pharmacokinetic model (PPK) identifying
CYP3A4 * 22 and CYP3A5 * 3 polymorphisms and hematocrit as explanatory variables of the
observed variability in pre-dose (Co) concentrations. According to this model, the proportion
of patients that do not reach the therapeutic target is 40